Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Senior Advisor O’Brien Emerges As Azar’s Lead On Drug Pricing In 2019

Executive Summary

O’Brien assumes role from his late colleague and friend Dan Best as HHS closes out administrative items in the blueprint.

You may also be interested in...



Beyond The "Blueprint": The Next Stage For US HHS Drug Price Policy

Upcoming transition in HHS drug pricing policy staff reinforces the Trump Administration's shift away from the 2018 "Blueprint” and towards engaging with bipartisan Congressional legislation – and spotlighting executive action as coming from the White House in the context of the upcoming Presidential campaign.

Carrots Or Sticks: Which Way Might Medicare's Protected Classes Reforms Go?

UnitedHealthcare program for commercial members offers some implications. MyScripRewards encourages less costly HIV treatments using financial rewards, underscoring insurers’ tendency to favor carrots over sticks when it comes to coverage policies for such drugs.

An Artificial Intelligence Milestone For US FDA

A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS124443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel